1Rock CL, Michael CW, Reynolds RK, et al. Prevention of cervix cancer. Crit Rev Oncol Hematol. 2000; 33(3):169-85.
2Mufioz N, Bosch FX, de Sanjos 6 S,et al.Epidemiologic classification of human papillomavirus types associated with cervical cancer. N EnglJ Med. 2003; 348(6):518-27.
3Trottier H, Burchell AN. Epidemiology of mucosal human papillomavirus infection and associated diseases. Public Health Genomics. 2009, 12:291 307.
4Yuan X, Yang Y, Gu D,et al.Prevalence of human papillomavirus infection among women with and without normal cervical histology in Shandong Province, China. Arch Gynecol Obstet. 2011 ; 283 (6):1385-9.
5Trottier H, Franco EL.The epidemiology of genital human papillomavirus infection. Vaccine. 2006, 24:1-15.
6Munoz N, Bosch FX, Castellsague X, et al. Against which human papil-lomavirus types shall we vaccinate and screen? The international perspective, nt J Cancer, 2004, 1,11: 278-285.
7Vinodhini K, Shanmughapriya S, Das BC,et al. Prevalence and risk factors of HPV infection among women from various provinces of the world. Arch Gynecol Obstet. 2012; 285(3):771-777.
同被引文献21
1Sderlund-Strand A,Kjellberg L,Dillner J.Human papillo- mavirus type-specific persistence and recurrence after treatment for cervical dysplasia[J].J Med Virol,2014,86(4):634-641.
2Luna J,Plata M,Gonzalez M,et al.Long-term follow-up observation of the safety,immunogenicity,and effective- ness of Gardasil in adult women[J].PLos One,2013,8(12):83431.
